Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
9.28
-5.66 (-37.88%)
At close: Aug 1, 2025, 4:00 PM
9.45
+0.17 (1.83%)
After-hours: Aug 1, 2025, 4:51 PM EDT

Company Description

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.

The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.

Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.

The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Silexion Therapeutics Corp
Silexion Therapeutics logo
CountryIsrael
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees14
CEOIlan Hadar

Contact Details

Address:
The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center
Jerusalem, 9112001
Israel
Phone972 2 674 3430
Websitesilexion.com

Stock Details

Ticker SymbolSLXN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0002022416
ISIN NumberKYG1281K1224
SIC Code2836

Key Executives

NamePosition
Ilan Hadar M.B.A.Chairman and Chief Executive Officer
Mirit Horenshtein HadarExecutive Vice President of Finance Affairs, Chief Financial Officer and Secretary
Dr. Mitchell Shirvan M.B.A., Ph.D.Chief Scientific and Development Officer

Latest SEC Filings

DateTypeTitle
Jul 31, 20258-KCurrent Report
Jul 31, 2025DEF 14AOther definitive proxy statements
Jul 29, 20258-KCurrent Report
Jul 21, 20258-KCurrent Report
Jul 21, 2025PRE 14AOther preliminary proxy statements
Jul 16, 20258-KCurrent Report
Jul 14, 20258-KCurrent Report
Jul 9, 20258-KCurrent Report
Jul 8, 20258-K/A[Amend] Current report
Jul 8, 20258-KCurrent Report